Comparative Pharmacology
Head-to-head clinical analysis: FILSPARI versus VALSARTAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FILSPARI versus VALSARTAN.
FILSPARI vs VALSARTAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FILSPARI (sparsentan) is an endothelin receptor antagonist (ERA) and angiotensin II receptor blocker (ARB) with high affinity for the endothelin type A (ETA) receptor and angiotensin II type 1 (AT1) receptor. It reduces proteinuria in IgA nephropathy by inhibiting endothelin-1 mediated vasoconstriction, inflammation, and fibrosis, and by blocking angiotensin II mediated effects.
Valsartan is an angiotensin II receptor antagonist (ARB) that selectively blocks the binding of angiotensin II to the AT1 receptor, resulting in vasodilation, reduced aldosterone secretion, and decreased blood pressure.
200 mg orally once daily, with or without food.
80-320 mg orally once daily; initial dose typically 80 mg or 160 mg once daily.
None Documented
None Documented
Clinical Note
moderateValsartan + Torasemide
"The risk or severity of adverse effects can be increased when Valsartan is combined with Torasemide."
Clinical Note
moderateValsartan + Etacrynic acid
"The risk or severity of adverse effects can be increased when Valsartan is combined with Etacrynic acid."
Clinical Note
moderateValsartan + Furosemide
"The risk or severity of adverse effects can be increased when Valsartan is combined with Furosemide."
Clinical Note
moderateValsartan + Bumetanide
Terminal half-life ~30 hours in healthy subjects, supporting once-daily dosing.
Terminal elimination half-life is approximately 6 hours (range 4–9 hours) in healthy adults. In patients with hepatic impairment, half-life is similar due to lack of significant metabolism.
Primarily hepatic metabolism; <1% excreted unchanged in urine. ~59% of dose recovered in feces and ~27% in urine as metabolites.
Primarily eliminated unchanged in feces (83%) via biliary excretion, and approximately 13% in urine as unchanged drug. Renal clearance accounts for ~30% of total clearance.
Category C
Category D/X
Endothelin Receptor Antagonist / ARB
ARB
"The risk or severity of adverse effects can be increased when Valsartan is combined with Bumetanide."